Objectives: The antimicrobial activity of telavancin against 2279 clinical Gram-positive cocci obtained from patients with nosocomial pneumonia [NP; including those with ventilator-acquired pneumonia (VAP)] located in numerous medical centres worldwide was evaluated.
Introduction
Nosocomial pneumonia (NP) is currently the second most common nosocomial infection in the USA and is associated with high morbidity and mortality. 1 -4 NP may be further delineated into hospital-acquired pneumonia (HAP; pneumonia that occurs 48 h or more after admission), ventilator-associated pneumonia (VAP; pneumonia that arises more than 48 -72 h after endotracheal intubation) and healthcare-associated pneumonia [infections that occur prior to hospital admission in patients with specific risk factors (immunosuppression, recent hospitalization, residence in a nursing facility, dialysis requirement)]. 1 -3,5 NP accounts for up to 25% of all intensive care unit (ICU) infections and for more than 50% of antibacterial agent prescriptions. 6 VAP occurs in 9%-27% of all intubated patients, and in some ICU patient populations nearly 90% of episodes of NP occur during mechanical ventilation. 1, 7 The presence of NP increases hospital stay by an average of 7 -9 days per patient and has been reported to produce an excess healthcare cost of more than $40000 per patient. 2 The increased or 'attributable' mortality related to NP has been estimated to be between 33% and 50% in several studies. 1, 2 A variety of infectious organisms can cause NP. 2 Although aerobic Gram-negative bacilli (e.g. Pseudomonas aeruginosa, Acinetobacter spp. and Enterobacteriaceae) continue to be important, infections due to Gram-positive cocci such as Staphylococcus aureus, particularly methicillin (oxacillin)-resistant S. aureus (MRSA), have been rapidly emerging in the USA and elsewhere. 2, 6, 8 Notably, analysis of a large US inpatient database revealed that, among all pathogens associated with NP, S. aureus was the only pathogen associated with significantly increased mortality. 2 In contrast to S. aureus, Gram-positive respiratory tract commensals, such as viridans group streptococci (VGS), enterococci and coagulasenegative staphylococci (CoNS), are usually not considered causative agents in NP. 2, 5 However, significant growth of these organisms from invasive bronchial specimens may be difficult to interpret, but they may produce infections in immunocompromised hosts and rarely in immunocompetent patients. 9 Moreover, Streptococcus pneumoniae is commonly responsible for community-acquired pneumonia, but usually this pathogen represents fewer than 10% of NP cases. 10 Telavancin is an intravenous, semisynthetic, lipoglycopeptide that is broadly active against both aerobic and anaerobic Grampositive bacteria, including streptococci, methicillin-susceptible S. aureus (MSSA), MRSA, and some vancomycin-resistant enterococci (VRE). 11 -16 Against S. aureus with reduced susceptibility to glycopeptides, telavancin showed slightly elevated MIC values that were still below the approved breakpoint for susceptibility (≤1 mg/L). 17 -20 Telavancin is bactericidal by means of two mechanisms acting in concert: (i) interference with cell wall synthesis by potent binding to the cell wall precursor lipid II, thereby preventing polymerization (transglycosylation) and cross-linking (transpeptidation) events; and (ii) binding to lipid II and inserting a hydrophobic anchor into the bacterial lipid membrane, resulting in depolarization and disruption of the functional integrity of the membrane. 21, 22 In this report, we summarize the 2007-08 results of an international surveillance programme comparing the in vitro activity of telavancin and currently marketed glycopeptides with other antimicrobial agents against Gram-positive clinical isolates obtained from respiratory tract specimens from patients with NP. A total of 2279 bacterial strains were tested by reference CLSI methods with susceptibilities to comparator agents interpreted by CLSI breakpoint criteria.
Methods

Bacterial clinical isolates
A total of 2279 consecutive, non-duplicate Gram-positive clinical strains were collected and referred by 87 hospitals located in North America (913 strains), Latin America (222), Europe (690), and the Asia-Pacific region (APAC; 454) as part of the international telavancin surveillance programme for 2007-08. Isolates were obtained from patients with pneumonia considered to be clinically significant by local criteria and occurring more than 72 h after hospitalization. The bacterial collection included 1756 S. aureus (77.1% of total; 45% MRSA), 20 CoNS (0.9% of total; 95% oxacillin-resistant), 314 S. pneumoniae (13.7% of total; 47.1% penicillin-non-susceptible at ≥0.12 mg/L), 30 VGS (1.3% of total; 63.3% penicillin-non-susceptible), 61 b-haemolytic streptococci (BHS; 2.7% of total; 19.7% macrolide-resistant) and 98 enterococci (4.3% of total; 14.3% VRE).
Appropriate specimens included bronchoalveolar lavage, tracheal aspirates, protected brush and high-quality Gram stain screened sputums. 23 All isolates were shipped to the monitoring laboratories (JMI Laboratories, North Liberty, IA, USA and Women's and Children's Hospital, North Adelaide, South Australia) on charcoal transport swabs for confirmation of organism identification and reference susceptibility testing. 24 Identification was performed by using conventional algorithms and the Vitek w 2 Microbial Identification System (Biomérieux, Hazelwood, MO, USA), when necessary.
Susceptibility test methods
All strains were tested by the broth microdilution method 24 using commercial validated panels (Trek Diagnostics, Cleveland, OH, USA) in cation-adjusted Mueller-Hinton broth (with 2% -5% lysed horse blood added for testing of streptococci). Telavancin and the comparator antimicrobial agents were obtained from the respective manufacturers. For enterococci, the VanA phenotype was characterized by non-susceptibility to vancomycin and teicoplanin, while isolates with a VanB phenotype were those non-susceptible to vancomycin but susceptible to teicoplanin according to CLSI criteria. 25 Interpretation of comparator MIC results was in accordance with published CLSI criteria. 25 Telavancin-susceptible breakpoints for S. aureus (≤1 mg/L), BHS and VGS (≤0.12 mg/L) and vancomycin-susceptible enterococci (VSE) (≤1 mg/L) were those recently approved by the US FDA.
18 Quality control strains used included S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212 and S. pneumoniae ATCC 49619. 25 
Results
Bacterial clinical isolates
S. aureus was the predominant Gram-positive respiratory tract pathogen in all four monitored regions, ranging from 46.3% of strains in the APAC region to 91.9% in North America. The lowest frequency of MRSA (28.9% of S. aureus) was observed in Europe and the highest (60.1%) in Latin America. S. pneumoniae accounted for fewer than 10% of Gram-positive respiratory tract strains in all regions with the exception of the APAC region (43.4%). This region also had the highest rate of penicillin-nonsusceptible pneumococci (38.1% resistant and 12.2% intermediate). The remaining Gram-positive respiratory tract pathogens each accounted for less than 5% of the total number of isolates from any given region with the exception of Enterococcus spp., which accounted for 9.3% of European strains. The highest frequency of VRE (all E. faecium) was detected among Enterococcus spp. from North America (38.5%).
Telavancin spectrum of activity
Telavancin had potent activity against staphylococcal, streptococcal and enterococcal isolates (Table 1) . Telavancin inhibited all S. pneumoniae, VGS (100% susceptible) and BHS (100% susceptible) at ≤0.12 mg/L, all S. aureus (100% susceptible) and CoNS at ≤0.5 mg/L and all vancomycin-susceptible enterococci at ≤1 mg/L (100% susceptible). Among E. faecium nonsusceptible to vancomycin, six isolates showed a VanA phenotype, while 10 strains displayed a VanB phenotype. Isolates with the VanA phenotype exhibited telavancin MIC values ≥2 mg/L, whereas VanB-type isolates were inhibited by lower concentrations of telavancin with MIC values at ≤0.12 mg/L (MIC 50/90 , 0.06/0.12 mg/L; Table 1 ). Oxacillin resistance among staphylococci and penicillin-non-susceptibility among streptococci had no effect on telavancin potency (MIC 90 ) compared with the respective susceptible populations. There was no geographic variation in the potency of telavancin against isolates of S. aureus or other pathogens (data not shown).
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In vitro activity of telavancin and comparator agents
The telavancin MIC 90 values for MSSA, MRSA and CoNS were 2-to 32-fold lower than those of vancomycin, teicoplanin, daptomycin, linezolid and quinupristin/dalfopristin (Table 2) . Among the staphylococci tested, there were 60 S. aureus and 13 CoNS isolates for which vancomycin MIC values were 2 mg/L. Linezolid MIC values were ≥4 mg/L for five isolates of S. aureus (four were MRSA); the telavancin MIC results for all of these strains were ≤0.5 mg/L. Levofloxacin, erythromycin, clindamycin and gentamicin all exhibited very limited activity against MRSA and CoNS. Modest anti-staphylococcal activity was also observed for tetracycline and trimethoprim/sulfamethoxazole (82.4% and 88.3% of MRSA were susceptible, respectively).
Among all agents tested, telavancin had the greatest potency against S. pneumoniae, with an MIC 90 of 0.03 mg/L, regardless of resistance to penicillin or other agents. Notably, 6.5% of penicillinresistant pneumococci were resistant to levofloxacin and none was non-susceptible to linezolid. Among the VGS and BHS, 50.0% and 19.7%, respectively, were resistant to erythromycin. Telavancin demonstrated potent activity against these organisms (MIC 90, 0.06 mg/L for both groups), unaffected by their susceptibility to erythromycin. Telavancin had MIC values ranging from ≤0.015 to 1 mg/L against VSE and it was 4-to 8-fold more potent than all of the comparators.
Discussion
As noted previously, 2,3,10,26 S. aureus was the dominant Gram-positive pathogen in all geographic regions, although the frequency of occurrence and resistance to methicillin (oxacillin) did vary considerably. Telavancin exhibited potent activity against all S. aureus (100% susceptible) and CoNS irrespective of resistance to other classes of antimicrobial agents. Although 99% -100% of MRSA were susceptible to vancomycin, teicoplanin, daptomycin, linezolid and quinupristin/dalfopristin according to CLSI interpretive criteria, telavancin was generally 2-to 8-fold more potent than these currently used agents against this important multidrug-resistant pathogen. Whereas glycopeptidenon-susceptible strains of S. aureus were not detected in this survey, it is notable that the vancomycin MIC was 2 mg/L for 60 isolates (3.4% of total). Although such strains are considered susceptible, it is now apparent that elevated vancomycin MIC results, defined as 1.5-2 mg/L, are an independent predictor of poor response to vancomycin therapy for MRSA infection, even when vancomycin trough levels .15 mg/L are achieved. 3,27 -29 One MRSA isolate showed a resistant phenotype to linezolid (MIC, 8 mg/L; Table 2 ). An additional four isolates (three MRSA) showed elevated MIC results of 4 mg/L for linezolid. The telavancin MIC values for all five of these isolates were ≤0.5 mg/L.
Resistance to penicillin and the macrolides was common among isolates of S. pneumoniae and VGS from all regions. Although S. pneumoniae was the second most common Grampositive respiratory tract isolate in all four regions, it was more prominent in the APAC region (43.4% of all isolates) than in the other three regions (5.0%-8.3%; data not shown). Whereas S. pneumoniae is a well-known cause of community-acquired pneumonia (CAP), it is also observed as a cause of early-onset HAP (within the first 4 days of hospitalization) and is an uncommon cause of late-onset (5 days or more) infection.
1,2 Telavancin Pfaller et al. Telavancin had MIC 90 values that were 4-fold lower than those of vancomycin, teicoplanin, daptomycin, linezolid and quinupristin/dalfopristin against VSE isolates, but was less potent than daptomycin and linezolid against vancomycin-non-susceptible enterococci. Among these isolates, telavancin was highly active against all VanB isolates (MIC, ≤0.12 mg/L), and it was only adversely affected when tested against strains exhibiting a VanA phenotype (MIC, ≥2 mg/L).
In summary, this report confirms the potency and spectrum of telavancin against Gram-positive NP pathogens collected from four broad geographic regions between 2007 and 2008.
In particular, we have demonstrated the superior in vitro potency of this agent compared with currently marketed antistaphylococcal agents against more than 1700 S. aureus clinical isolates from five continents. These data, in addition to recent clinical trial results in the treatment of NP, support telavancin as a potential therapeutic option for serious infections. 30 Continued surveillance to monitor telavancin activity, especially against staphylococci, will be critical in assessing the long-term utility of this promising new agent. 
